LIFE aTyr Pharma, Inc.

3.40
-0.10  -3%
Previous Close 3.50
Open 3.45
Price To book 1.64
Market Cap 80.94M
Shares 23,806,000
Volume 25,287
Short Ratio 1.93
Av. Daily Volume 121,217

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data presented at EASL 2017.
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)

Latest News

  1. aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
  2. Atyr Pharma reports 1Q loss
  3. aTyr Pharma Announces First Quarter 2017 Operating Results
  4. aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
  5. aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy
  6. aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
  7. aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
  8. aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
  9. aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases
  10. aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  11. aTyr Pharma Rises 16% on Orphan Drug Status
  12. aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference
  13. aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  14. High court ruling limits international reach of patent laws
  15. Atyr Pharma Stock Spikes 33% on FDA Updates
  16. FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
  17. Roberts recuses from patent case after discovering conflict
  18. Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
  19. Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?